Search Results - Planchard, David

Refine Results
  1. 1
    Editorial on the article entitled “brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial”

    Editorial on the article entitled “brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial” by Sullivan, Ivana, Planchard, David

    Published 2016
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  2. 2
    Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line

    Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line by Sullivan, Ivana, Planchard, David

    Published 2017
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  3. 3
    The role of brigatinib in crizotinib-resistant non-small cell lung cancer

    The role of brigatinib in crizotinib-resistant non-small cell lung cancer by Mezquita, Laura, Planchard, David

    Published 2018
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  4. 4
    Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience

    Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience by Sullivan, Ivana, Planchard, David

    Published 2016
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  5. 5
    Oncogene addiction and immune escape: friends or foes?

    Oncogene addiction and immune escape: friends or foes? by Abdayem, Pamela, Planchard, David

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  6. 6
    FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression

    FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression by Abdayem, Pamela, Planchard, David

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  7. 7
    Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience

    Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience by Botticella, Angela, Mezquita, Laura, Le Pechoux, Cecile, Planchard, David

    Published 2019
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  8. 8
    Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report

    Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report by Niu, Xiaomin, Sun, Yingjia, Planchard, David, Chiu, Luting, Bai, Jian, Ai, Xinghao, Lu, Shun

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  9. 9
    Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib

    Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib by Facchinetti, Francesco, Levy, Antonin, Ammari, Samy, Naltet, Charles, Lavaud, Pernelle, Aldea, Mihaela, Vasseur, Damien, Planchard, David, Besse, Benjamin

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  10. 10
    Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer

    Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer by Schernberg, Antoine, Mezquita, Laura, Boros, Angela, Botticella, Angela, Caramella, Caroline, Besse, Benjamin, Escande, Alexandre, Planchard, David, Le Péchoux, Cécile, Deutsch, Eric

    Published 2018
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  11. 11
    Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease

    Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease by Herrera-Gómez, Ruth Gabriela, Grecea, Miruna, Gallois, Claire, Boige, Valérie, Pautier, Patricia, Pistilli, Barbara, Planchard, David, Malka, David, Ducreux, Michel, Mir, Olivier

    Published 2022
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  12. 12
    Staging of nutrition disorders in non‐small‐cell lung cancer patients: utility of skeletal muscle mass assessment

    Staging of nutrition disorders in non‐small‐cell lung cancer patients: utility of skeletal muscle mass assessment by Antoun, Sami, Morel, Hugues, Souquet, Pierre‐Jean, Surmont, Veerle, Planchard, David, Bonnetain, Franck, Foucher, Pascal, Egenod, Thomas, Krakowski, Ivan, Gaudin, Hélène, Debieuvre, Didier

    Published 2019
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  13. 13
    ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer

    ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer by Passaro, Antonio, Addeo, Alfredo, Von Garnier, Christophe, Blackhall, Fiona, Planchard, David, Felip, Enriqueta, Dziadziuszko, Rafal, de Marinis, Filippo, Reck, Martin, Bouchaab, Hasna, Peters, Solange

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  14. 14
    Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience

    Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience by Lamy, Tina, Cabarrou, Bastien, Planchard, David, Quantin, Xavier, Schneider, Sophie, Bringuier, Michael, Besse, Benjamin, Girard, Nicolas, Chouaid, Christos, Filleron, Thomas, Simon, Gaëtane, Baldini, Capucine

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  15. 15
    Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab: A Case Report

    Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab: A Case Report by Riudavets, Mariona, Wyplosz, Benjamin, Ghigna, Maria Rosa, Botticella, Angela, Abdayem, Pamela, Pradere, Pauline, Kasraoui, Ines, Roux, Charles, Le Pechoux, Cécile, Garcia, Camilo, Planchard, David

    Published 2022
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  16. 16
    Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non–Small Cell Lung Cancer

    Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non–Small Cell Lung Cancer by Kas, Baptiste, Talbot, Hugues, Ferrara, Roberto, Richard, Colombe, Lamarque, Jean-Philippe, Pitre-Champagnat, Stéphanie, Planchard, David, Balleyguier, Corinne, Besse, Benjamin, Mezquita, Laura, Lassau, Nathalie, Caramella, Caroline

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  17. 17
    Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients

    Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients by Boros, Angela, Lacroix, Ludovic, Lacas, Benjamin, Adam, Julien, Pignon, Jean-Pierre, Caramella, Caroline, Planchard, David, de Montpreville, Vincent, Deutsch, Eric, Levy, Antonin, Besse, Benjamin, Pechoux, Cécile Le

    Published 2017
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  18. 18
    Integrin-α(V)-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade

    Integrin-α(V)-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade by Malenica, Ines, Adam, Julien, Corgnac, Stéphanie, Mezquita, Laura, Auclin, Edouard, Damei, Isabelle, Grynszpan, Laetitia, Gros, Gwendoline, de Montpréville, Vincent, Planchard, David, Théret, Nathalie, Besse, Benjamin, Mami-Chouaib, Fathia

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  19. 19
    Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

    Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors by Oulhen, Marianne, Pawlikowska, Patrycja, Tayoun, Tala, Garonzi, Marianna, Buson, Genny, Forcato, Claudio, Manaresi, Nicolò, Aberlenc, Agathe, Mezquita, Laura, Lecluse, Yann, Lavaud, Pernelle, Naltet, Charles, Planchard, David, Besse, Benjamin, Farace, Françoise

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  20. 20
    A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer

    A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer by Yamamoto, Nobuyuki, Hayashi, Hidetoshi, Planchard, David, Morán, Teresa, Gregorc, Vanesa, Dowell, Jonathan, Sakai, Hiroshi, Yoh, Kiyotaka, Nishio, Makoto, Cortot, Alexis B., Benhadji, Karim A., Soni, Nital, Huang, Jinhong, Makris, Lukas, Cedres, Susana

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:

Search Tools: